US Stock MarketDetailed Quotes
SAGE Sage Therapeutics
- 13.690
- +0.110+0.81%
Close Apr 26 16:00 ET
- 13.500
- -0.190-1.39%
Post 16:59 ET
823.89MMarket Cap-1631P/E (TTM)
13.910High13.380Low1.49MVolume13.870Open13.580Pre Close20.42MTurnover3.14%Turnover RatioLossP/E (Static)60.18MShares59.99052wk High1.17P/B651.99MFloat Cap10.92052wk Low--Dividend TTM47.63MShs Float195.970Historical High--Div YieldTTM3.90%Amplitude10.920Historical Low13.668Avg Price1Lot Size
Sage Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 75.38%-37.83M | -17.51%-540.59M | 5.84%-119.52M | -14.30%-135.87M | -23.56%-131.52M | -42.56%-153.68M | -21.64%-460.04M | -30.19%-126.93M | -72.70%-118.87M | -3.57%-106.44M |
| Net income from continuing operations | 26.12%-108.48M | -1.63%-541.49M | 77.77%-32.71M | -46.83%-201.63M | -26.98%-160.33M | -20.30%-146.83M | -16.36%-532.78M | -17.99%-147.15M | -5.49%-137.32M | -17.73%-126.26M |
| Operating gains losses | 20.69%-23K | 91.20%-132K | -69.44%-61K | --0 | 84.15%-42K | 97.56%-29K | 93.66%-1.5M | 99.06%-36K | 99.66%-10K | 96.43%-265K |
| Depreciation and amortization | 4.02%336K | 24.15%1.39M | 41.03%409K | 18.71%330K | 18.64%331K | 17.45%323K | -73.17%1.12M | -12.91%290K | -25.67%278K | -68.76%279K |
| Change In working capital | 342.40%58.19M | -1,288.22%-67.38M | -1,858.26%-106.29M | 954.74%41.69M | 719.15%21.22M | -247.07%-24.01M | 130.64%5.67M | 5.04%6.05M | -84.51%3.95M | 112.93%2.59M |
| -Change in receivables | 5,502.38%72.5M | -1,531.06%-69.35M | -1,363.49%-60.5M | -240.75%-7.42M | 97.76%-88K | -3.95%-1.34M | 126.19%4.85M | -15.69%4.79M | -78.25%5.27M | 83.42%-3.93M |
| -Change in prepaid assets | 165.27%5.24M | 272.97%19M | 31.45%2.88M | 200.47%11.62M | 394.87%12.53M | -404.52%-8.02M | 35.46%-10.99M | 139.85%2.19M | -110.33%-11.56M | 26.27%-4.25M |
| -Change in payables and accrued expense | -31.31%-19.62M | -210.06%-14.36M | -5,421.87%-48.48M | 258.89%37.43M | 3.29%11.63M | -92.56%-14.94M | -29.26%13.05M | -114.42%-878K | 45.57%10.43M | 15.59%11.26M |
| -Change in other current assets | -2.62%1.93M | -15.07%4.3M | 2.28%1.61M | 30.06%1.83M | -206.39%-1.13M | 96.53%1.99M | 17.33%5.06M | 66.53%1.58M | 37.94%1.41M | 0.19%1.06M |
| -Change in other current liabilities | -10.20%-1.86M | -10.65%-6.97M | -10.35%-1.8M | -10.34%-1.76M | -10.48%-1.72M | -11.50%-1.69M | -9.76%-6.3M | -11.62%-1.63M | -11.84%-1.6M | -11.62%-1.56M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 75.38%-37.83M | -17.51%-540.59M | 5.84%-119.52M | -14.30%-135.87M | -23.56%-131.52M | -42.56%-153.68M | -21.64%-460.04M | -30.19%-126.93M | -72.70%-118.87M | -3.57%-106.44M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -28.45%139.44M | 36.10%442.91M | -53.15%42.06M | 44.56%160.39M | -66.04%45.59M | 2,138.78%194.87M | 132.46%325.43M | 396.68%89.78M | 544.11%110.95M | 146.56%134.26M |
| Net PPE purchase and sale | --0 | 40.98%-553K | 139.72%112K | 9.89%-328K | 8.20%-112K | -33.14%-225K | -151.88%-937K | 24.19%-282K | ---364K | ---122K |
| Net investment purchase and sale | -28.53%139.44M | 35.88%443.47M | -53.42%41.95M | 44.38%160.72M | -65.99%45.71M | 2,177.88%195.09M | 132.57%326.37M | 401.31%90.06M | 545.57%111.32M | 146.60%134.38M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -28.45%139.44M | 36.10%442.91M | -53.15%42.06M | 44.56%160.39M | -66.04%45.59M | 2,138.78%194.87M | 132.46%325.43M | 396.68%89.78M | 544.11%110.95M | 146.56%134.26M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -41.73%1.56M | 96.32%6.03M | -1,003.45%-262K | 125.39%2.77M | 6,415.38%847K | 48.53%2.67M | -76.98%3.07M | 117.06%29K | -32.32%1.23M | -99.79%13K |
| Proceeds from stock option exercised by employees | -52.77%1.56M | 122.61%6.93M | --0 | 122.99%2.77M | 2,210.81%855K | 83.49%3.3M | -78.85%3.11M | -92.12%33K | -31.50%1.24M | -99.46%37K |
| Net other financing activities | 99.68%-2K | -2,000.00%-903K | -6,450.00%-262K | 73.33%-4K | ---8K | ---629K | 96.90%-43K | 99.32%-4K | ---15K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -41.73%1.56M | 96.32%6.03M | -1,003.45%-262K | 125.39%2.77M | 6,415.38%847K | 48.53%2.67M | -76.98%3.07M | 117.06%29K | -32.32%1.23M | -99.79%13K |
| Net cash flow | ||||||||||
| Beginning cash position | -55.89%72.32M | -44.51%163.97M | -25.39%150.04M | -40.92%122.75M | 15.50%207.83M | -44.51%163.97M | -82.23%295.5M | -52.51%201.1M | -59.69%207.78M | -80.02%179.94M |
| Current changes in cash | 135.22%103.16M | 30.33%-91.65M | -109.34%-77.72M | 508.38%27.3M | -405.64%-85.08M | 137.95%43.86M | 90.38%-131.53M | 70.98%-37.13M | 92.73%-6.68M | 107.23%27.84M |
| End cash Position | -15.56%175.49M | -55.89%72.32M | -55.89%72.32M | -25.39%150.04M | -40.92%122.75M | 15.50%207.83M | -44.51%163.97M | -44.51%163.97M | -52.51%201.1M | -59.69%207.78M |
| Free cash flow | 75.42%-37.83M | -17.39%-541.14M | 6.14%-119.41M | -14.23%-136.19M | -23.53%-131.63M | -42.55%-153.91M | -21.77%-460.97M | -29.98%-127.21M | -73.23%-119.23M | -3.69%-106.56M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg